Etablierung der CDK4/6-Inhibitoren als neuer SOC für die Behandlung des mBC

Im Interview berichtet Assoc.-Prof. PD Dr. Rupert Bartsch von einer neuen Auswertung der Studien PALOMA-2 und -3 und Real-World-Daten zu CDK4/6-Inhibitoren, die am ESMO-Kongress präsentiert wurden.

Referenzen

1. Graff PO et al.: The CDK4/6 inhibitors takeover of the HR+/HER2- locally advanced to metastatic breast cancer market in the EU5: Findings from a real-world study. ESMO 2021, Abstr. #249P

2. Rugo HS et al.: Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3). ESMO 2021, Abstr. #234P

3. Palmieri C et al.: A real-world data analysis: The first United Kingdom experience of cyclin-dependent kinase 4/6 inhibitor in advanced breast cancer in the National Health Service within an access program. ESMO 2021, Abstr. #240P

4. Rugo HS et al.: Real-world comparative effectiveness of palbociclib plus letrozole vs letrozole in older patients with metastatic breast cancer. ESMO 2021, Abstr. #236P

5. El Badri S et al.: Palbociclib combined with aromatase inhibitors (AIs) in women ≥75 years with oestrogen receptor positive (ER+ve), human epidermal growth factor receptor 2 negative (HER2-ve) advanced breast cancer: A real-world multicentre UK study. ESMO 2021, Abstr. #245P

6. Fouda MM et al.: CDK4/6 inhibitors in clinical practice during COVID-19 pandemic: Comparative analysis of the clinical impact of the pandemic for metastatic breast cancer patients during first and second waves in the UK. ESMO 2021, Abstr. #243P

Entgeltliche Einschaltung
Mit freundlicher Unterstützung von Pfizer Corporation Austria Gesellschaft m. b. H.
www.pfizer.at
www.pfizermed.at
PP-IBR-AUT-0484/09.2021